CRISPR-Cas9 Technology for Precision Cardiovascular Medicine

CRISPR/Cas9 technology emerged as a critical tool in cardiovascular medicine to enable genome editing and engineer novel therapies. Use of CRISPR for correcting mutations has transformed the research on dyslipidemia, atherosclerosis, and cardiomyopathies. The synergism between CRISPR and artificial intelligence (AI) enhance accuracy by optimizing guide RNA design, minimizing off-target effects, and maximizing delivery strategies. Additionally, CRISPR editing systems like CRISPRoff/CRISPRon enable modulation of gene expression without genome changes, hence offer therapeutic intervention. Its uses in cardiovascular systems biology have also solved precise disease modeling, enabled high-resolution decomposition of mechanisms, and drug discovery. Although its potential is great, its clinical translation is foiled by safety, long-term efficacy, ethical, and equal accessibility issues. Expanding the CRISPR platform with base and prime editing has potential to circumvent these limitations, positioning CRISPR as a keystone technology in driving cardiovascular medicine.